Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
Status:
Completed
Trial end date:
2020-09-04
Target enrollment:
Participant gender:
Summary
RATIONALE: Autologous stem cell transplantation may be effective treatment for primary
systemic (AL) amyloidosis.
PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell
transplantation works in treating patients with primary systemic (AL) amyloidosis.